Last reviewed · How we verify
NCT07011329: NPC
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
trial testing Changes in the brain MTP parameters after radiotherapy in Nasopharyngeal Carcinoma (NPC) in 60 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Hubei Cancer Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 April 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Changes in the brain MTP parameters after radiotherapy
Conditions studied
- Nasopharyngeal Carcinoma (NPC) — all drugs for Nasopharyngeal Carcinoma (NPC) →
Sponsor
Hubei Cancer Hospital
Who can join
Adults 30 to 80, any sex, with Nasopharyngeal Carcinoma (NPC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to examine the potential impact of the treatment before, during, and/or after radiotherapy on the brain in patients with nasopharyngeal carcinoma (NPC) using Multiplex (MTP) MR imaging sequence, which generate multiple contrasts with one-time scan. We aimed to investigate the altered MTP parameters and their correlation with clinical cognitive scores before and after the treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07011329
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Carcinoma (NPC)
Currently open trials in the same condition.
- NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
- NCT06796270 — Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma · NA · recruiting
- NCT07340515 — Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial · Phase 3 · recruiting
- NCT07328841 — Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinom · Phase 3 · recruiting
- NCT07101744 — Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure · Phase 2 · recruiting
Other Hubei Cancer Hospital trials
Trials by the same sponsor.
- NCT07188857 — Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy · not yet recruiting
- NCT06402435 — SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer · Phase 2 · recruiting
- NCT06401005 — SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) · Phase 2 · recruiting
- NCT06712524 — Effect of Different Surgical Approaches of Granulomatous Mastitis · NA · recruiting
- NCT06714084 — CNCMT：a Multi-center, Prospective, Single-arm Study · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07011329 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hubei Cancer Hospital
- Last refreshed: 11 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07011329.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing